	Application No.	Applicant(s)	•
Notice of Allowability	10/538,902.	KAPLAN, JEFFREY	В.
	Examiner .	Art Unit	
••••••••••••••••••••••••••••••••••••••	Elizabeth Slobodyansky, PhD	1652	
The MAILING DATE of this communication appearance All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIPLY of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	plication. If not include will be mailed in due	ed course. THIS
1. 🖂 This communication is responsive to <u>amendment 16 August 2007</u> .			
2. X The allowed claim(s) is/are 7,10,11,15,21,26,35 and 36.			
 Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). 	been received. been received in Application No		tion from the
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			OTICE OF
5. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the statement sheet in the statement sheet.	on's Patent Drawing Review (PTO-9). s Amendment / Comment or in the O .84(c)) should be written on the drawir	ffice action of	back) of
 DEPOSIT OF and/or INFORMATION about the depo- attached Examiner's comment regarding REQUIREMENT 	sit of BIOLOGICAL MATERIAL n FOR THE DEPOSIT OF BIOLOGICA	nust be submitted. N AL MATERIAL.	lote the
			,
Attachment(s)	5 Matica of Informal D	-44	
 Notice of References Cited (PTO-892) Dotice of Draftperson's Patent Drawing Review (PTO-948) 	5. ☐ Notice of Informal P6. ☐ Interview Summary	* *	
Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 8/16/07	Paper No./Mail Dat 7. ⊠ Examiner's Amendn	e	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Stateme	nt of Reasons for Allo	wance
	9.		
	•		

DETAILED ACTION

The amendment filed August 16, 2007 canceling claims 1-6, 8, 9, 12-14, 16-20, 22-25 and 27-34 and amending claims 7, 10, 11, 15, 21 and 26 and adding claims 35 and 36 has been entered.

Claims 7, 10, 11, 15, 21, 26, 35 and 36 are pending. Claims 21 and 26 have been previously withdrawn.

Election/Restrictions

Claim 7 is directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(b), claims 21 and 26, directed to the process of making or using the allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Brian Dorn on September 10, 2007.

The application has been amended as follows:

IN THE CLAIMS:

Art Unit: 1652

In claim 21, line 2,

replace "bacterial cells" (after "contacting") with --the biofilm--.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

Thorough searches of the prior art revealed no previous teaching or suggestion of a polypeptide that cleaves β-substituted *N*-acetylglucosaminide or any other polypeptide from *Actinobacillus actinomycetemcomitans* or any other source having the amino acid sequence of SEQ ID NO:2 and a DNA encoding thereof, including SEQ ID NO:1.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth Slobodyansky, PhD whose telephone number is 571-272-0941. The examiner can normally be reached on M-F 10:00 - 6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, PhD can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1652

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Elizabeth Slobodyansky, PhD

Primary Examiner Art Unit 1652

September 10, 2007